Bortezomib - Latest Advances

Protein modification by a eukaryotic-like ubiquitin-related modifier in the hyperthermophilic archaeon Saccharolobus islandicus.

Journal: mSystems

Published: October 20, 2025

Pretreatment hemoglobin, myeloma subtype, and induction regimens as independent prognostic factors for survival after autologous stem cell transplantation in multiple myeloma: a retrospective cohort study.

Journal: Hematology (Amsterdam, Netherlands)

Published: October 14, 2025

Clinical characteristics and survival outcomes of patients with immunoglobulin A multiple myeloma in the bortezomib era: A single-center retrospective cohort study

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: October 14, 2025

Carfilzomib triggers cardiotoxicity by suppressing SENP1-mediated deSUMOylation of DDX17.

Journal: Acta biochimica et biophysica Sinica

Published: October 11, 2025

Treatment-emergent peripheral neuropathy associated with bortezomib-based frontline regimens for multiple myeloma.

Journal: Leukemia & lymphoma

Published: October 10, 2025

Biomimetic synthesis of a benzobisthiazole-based conjugated polymer for pH-responsive drug delivery and synergistic tumor therapy.

Journal: Chemical communications (Cambridge, England)

Published: October 09, 2025

A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.

Journal: Future oncology (London, England)

Published: October 08, 2025

The novel human astrovirus VA1 requires the proteasome during cell entry.

Journal: The Journal of general virology

Published: October 07, 2025

Treatment of transplant-ineligible newly diagnosed multiple myeloma: advances and future outlook

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: October 01, 2025

Data-Driven Drug Discovery Optimization for Breast Cancer Using Interpretable Machine Learning Models.

Journal: Journal of visualized experiments : JoVE

Published: September 29, 2025

Unraveling the role of PREX2 mutations as a biomarker for immunotherapy response in colorectal cancer.

Journal: Cancer biomarkers : section A of Disease markers

Published: September 19, 2025

Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma.

Journal: Journal of managed care & specialty pharmacy

Published: September 15, 2025

Filters

Protein modification by a eukaryotic-like ubiquitin-related modifier in the hyperthermophilic archaeon Saccharolobus islandicus.

Protein modification by a eukaryotic-like ubiquitin-related modifier in the hyperthermophilic archaeon Saccharolobus islandicus.

Pretreatment hemoglobin, myeloma subtype, and induction regimens as independent prognostic factors for survival after autologous stem cell transplantation in multiple myeloma: a retrospective cohort study.

Pretreatment hemoglobin, myeloma subtype, and induction regimens as independent prognostic factors for survival after autologous stem cell transplantation in multiple myeloma: a retrospective cohort study.

Clinical characteristics and survival outcomes of patients with immunoglobulin A multiple myeloma in the bortezomib era: A single-center retrospective cohort study

Clinical characteristics and survival outcomes of patients with immunoglobulin A multiple myeloma in the bortezomib era: A single-center retrospective cohort study

Carfilzomib triggers cardiotoxicity by suppressing SENP1-mediated deSUMOylation of DDX17.

Carfilzomib triggers cardiotoxicity by suppressing SENP1-mediated deSUMOylation of DDX17.

Treatment-emergent peripheral neuropathy associated with bortezomib-based frontline regimens for multiple myeloma.

Treatment-emergent peripheral neuropathy associated with bortezomib-based frontline regimens for multiple myeloma.

Biomimetic synthesis of a benzobisthiazole-based conjugated polymer for pH-responsive drug delivery and synergistic tumor therapy.

Biomimetic synthesis of a benzobisthiazole-based conjugated polymer for pH-responsive drug delivery and synergistic tumor therapy.

A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.

A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.

The novel human astrovirus VA1 requires the proteasome during cell entry.

The novel human astrovirus VA1 requires the proteasome during cell entry.

Treatment of transplant-ineligible newly diagnosed multiple myeloma: advances and future outlook

Treatment of transplant-ineligible newly diagnosed multiple myeloma: advances and future outlook

Data-Driven Drug Discovery Optimization for Breast Cancer Using Interpretable Machine Learning Models.

Data-Driven Drug Discovery Optimization for Breast Cancer Using Interpretable Machine Learning Models.

Unraveling the role of PREX2 mutations as a biomarker for immunotherapy response in colorectal cancer.

Unraveling the role of PREX2 mutations as a biomarker for immunotherapy response in colorectal cancer.

Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma.

Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma.